164 related articles for article (PubMed ID: 33769184)
21. Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.
Zhu Y; Wang H; Guo Y; Cao J; Li H
Mini Rev Med Chem; 2023; 23(19):1893-1904. PubMed ID: 37055897
[TBL] [Abstract][Full Text] [Related]
22. In silico anti-alzheimer study of phytochemicals from Lamiaceae family through GSK3-β inhibition.
Zareei S; Pourmand S; Eskandarzadeh M; Massahi S
Sci Rep; 2024 Jan; 14(1):834. PubMed ID: 38191548
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.
Schütz SV; Cronauer MV; Rinnab L
J Cell Biochem; 2010 Apr; 109(6):1192-200. PubMed ID: 20127713
[TBL] [Abstract][Full Text] [Related]
24. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of kinase inactivation and nonbinding of FRATide to GSK3β due to K85M mutation: molecular dynamics simulation and normal mode analysis.
Lu S; Jiang Y; Lv J; Zou J; Wu T
Biopolymers; 2011 Oct; 95(10):669-81. PubMed ID: 21442609
[TBL] [Abstract][Full Text] [Related]
27. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
28. Identifying Potential Ligand Binding Sites on Glycogen Synthase Kinase 3 Using Atomistic Cosolvent Simulations.
DasGupta D; Mehrani R; Carlson HA; Sharma S
ACS Appl Bio Mater; 2024 Feb; 7(2):588-595. PubMed ID: 37141501
[TBL] [Abstract][Full Text] [Related]
29. Structural basis for the complete loss of GSK3beta catalytic activity due to R96 mutation investigated by molecular dynamics study.
Zhang N; Jiang Y; Zou J; Yu Q; Zhao W
Proteins; 2009 May; 75(3):671-81. PubMed ID: 19003984
[TBL] [Abstract][Full Text] [Related]
30. Cyanidin-3-glucoside reverses ethanol-induced inhibition of neurite outgrowth: role of glycogen synthase kinase 3 Beta.
Chen G; Bower KA; Xu M; Ding M; Shi X; Ke ZJ; Luo J
Neurotox Res; 2009 May; 15(4):321-31. PubMed ID: 19384566
[TBL] [Abstract][Full Text] [Related]
31. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells.
Wang L; Lin HK; Hu YC; Xie S; Yang L; Chang C
J Biol Chem; 2004 Jul; 279(31):32444-52. PubMed ID: 15178691
[TBL] [Abstract][Full Text] [Related]
32. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
33. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
[TBL] [Abstract][Full Text] [Related]
34. GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.
Pardo M; Abrial E; Jope RS; Beurel E
Genes Brain Behav; 2016 Mar; 15(3):348-55. PubMed ID: 26749572
[TBL] [Abstract][Full Text] [Related]
35. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
36. Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3β pathway.
Zhu H; Han B; Pan X; Qi H; Xu L
J Clin Pharm Ther; 2012 Feb; 37(1):65-70. PubMed ID: 21410737
[TBL] [Abstract][Full Text] [Related]
37. P2 purinergic receptors signal to glycogen synthase kinase-3beta in astrocytes.
Neary JT; Kang Y
J Neurosci Res; 2006 Aug; 84(3):515-24. PubMed ID: 16810687
[TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
39. Unraveling the role of Arg4 and Arg6 in the auto-inhibition mechanism of GSK3β from molecular dynamics simulation.
Mou L; Li M; Lu SY; Li S; Shen Q; Zhang J; Li C; Lu X
Chem Biol Drug Des; 2014 Jun; 83(6):721-30. PubMed ID: 24444018
[TBL] [Abstract][Full Text] [Related]
40. AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming.
Zhang P; Song Y; Sun Y; Li X; Chen L; Yang L; Xing Y
FASEB J; 2018 Jul; 32(7):3924-3935. PubMed ID: 29505302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
